What is the link between diabetes and Alzheimer’s disease? C. Ronald Kahn, MD will present “Is Alzheimer’s Disease Type 3 Diabetes?” Dr. Kahn will discuss the correlation between the two, the effect of insulin resistance on brain function, and the potential use of antidiabetic medications in Alzheimer’s disease and dementia.
With regard to novel diabetes therapies, according to John B. Buse, MD, PhD, “I suspect that the combination of GLP-1 receptor agonists and basal insulin will become the default pathway of diabetes management in the future; and SGLT-2 inhibitors, as a once-daily oral medication, are compelled to play a central role in diabetes care moving forward.” Dr. Buse will discuss these points further in Type 2 Diabetes Management 2014, followed by Howard Wolpert, MD who will discuss the physiologic and practical considerations of initiating insulin therapy and avoiding the extremes of hyper- and hypoglycemia.
Treating Diabetes Automatically, 5 Minutes at a Time
Before the session concludes with a panel moderated by Jay S. Skyler, MD, Edward R. Damiano, PhD will present his research on the bionic pancreas, an unprecedented device that offers a holistic, fully automated systems approach to glycemic control in type 1 diabetes. Dr. Damiano said, “The bionic pancreas simultaneously solves the four greatest concerns of type 1 diabetes management: it reduces mean glycemia levels in excess of ADA goal (likely eradicating long-term microvascular complications); curtails mild hypoglycemia and likely eliminates risk of severe hypoglycemia; automates glycemic management; and unburdens the patient of fear and emotional hardship.”